NCT06059989View on ClinicalTrials.gov

InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Inflammatory DiseaseDisease CrohnBowel Disease
Interventions
DRUG

Infliximab subcutaneous

Mono and combination therapy group

DRUG

Immunosuppressive Agents

Combination group only

Trial Locations (1)

1105AZ

RECRUITING

Amsterdam UMC AMC, Amsterdam

Sponsors

Collaborators (1)

Celltrion
All Listed Sponsors
collaborator

Celltrion

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER